Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 3
2003 2
2004 12
2005 3
2006 9
2007 14
2008 14
2009 23
2010 22
2011 29
2012 34
2013 29
2014 22
2015 12
2016 9
2017 12
2018 8
2019 2
2020 7
2021 9
2022 2
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

266 results

Results by year

Filters applied: . Clear all
Page 1
Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Hypertension and Cardiovascular Risk Factors.
Oh J, Kim W, Kim GH, Kim HL, Park SD, Min KW, Hyun D, Hong JH, Lim S, Shin J; RESOLVE-INT Investigators. Oh J, et al. Adv Ther. 2023 Nov;40(11):4817-4835. doi: 10.1007/s12325-023-02632-9. Epub 2023 Aug 31. Adv Ther. 2023. PMID: 37651078 Free PMC article.
METHODS: This prospective, multicenter observational study assessed the real-world safety and effectiveness of an SPC containing olmesartan, amlodipine, and hydrochlorothiazide (O/A/H) in South Korean patients with hypertension and cardiovascular risk factors. ...
METHODS: This prospective, multicenter observational study assessed the real-world safety and effectiveness of an SPC containing olmesart …
Drugs for hypertension.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2020 May 18;62(1598):73-80. Med Lett Drugs Ther. 2020. PMID: 32555118 No abstract available.
Exploring the Effectiveness and Safety of Azilsartan-Medoxomil/Chlorthalidone Versus Olmesartan-Medoxomil/Hydrochlorothiazide in Hypertensive Patients: A Meta-Analysis.
Kumar L, Khuwaja S, Kumar A, Memon UA, Kumar M, Ashok A, Lohana M, Qudoos A, Kashif M, Khatri M, Kumar S, Sapna F, Dass A, Varrassi G. Kumar L, et al. Cureus. 2023 Jun 30;15(6):e41198. doi: 10.7759/cureus.41198. eCollection 2023 Jun. Cureus. 2023. PMID: 37525792 Free PMC article. Review.
This study aims to assess the effectiveness and safety of azilsartan-medoxomil/chlorthalidone (AZI-M/CT) compared to olmesartan-medoxomil/hydrochlorothiazide (OLM/HCTZ) in patients with hypertension. ...
This study aims to assess the effectiveness and safety of azilsartan-medoxomil/chlorthalidone (AZI-M/CT) compared to olmesartan-medox …
Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide.
Punzi HA. Punzi HA. Expert Rev Cardiovasc Ther. 2009 Mar;7(3):229-39. doi: 10.1586/14779072.7.3.229. Expert Rev Cardiovasc Ther. 2009. PMID: 19296759 Review.
It is likely that future hypertension guidelines will recommend lowering BP beyond the currently recommended systolic/diastolic BP goals of lower than 140/90 mmHg for all patients with hypertension and lower than 130/80 mmHg for patients with diabetes or chronic kidney disease. I …
It is likely that future hypertension guidelines will recommend lowering BP beyond the currently recommended systolic/diastolic BP goals of …
Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension.
Ram CV. Ram CV. Expert Rev Cardiovasc Ther. 2011 Jan;9(1):9-19. doi: 10.1586/erc.10.163. Expert Rev Cardiovasc Ther. 2011. PMID: 21166525 Review.
Regimens combining three or more antihypertensive agents have been shown to increase the proportion of patients achieving BP goals. Recent data suggest that the combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide is a rational treatment option of …
Regimens combining three or more antihypertensive agents have been shown to increase the proportion of patients achieving BP goals. Recent d …
Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension.
Ruilope LM. Ruilope LM. Vasc Health Risk Manag. 2008;4(6):1237-48. doi: 10.2147/vhrm.s3642. Vasc Health Risk Manag. 2008. PMID: 19337537 Free PMC article. Review.
The results presented here demonstrate that olmesartan is effective when added to HCTZ monotherapy or when HCTZ is added to olmesartan monotherapy, both over the short and long term. Moderate to severe hypertension responds well to olmesartan/HCTZ combination …
The results presented here demonstrate that olmesartan is effective when added to HCTZ monotherapy or when HCTZ is added to olmesa …
Pharmacokinetic properties and bioequivalence of olmesartan medoxomil/hydrochlorothiazide in healthy Korean male subjects.
Jin C, Jeon JY, Im YJ, Jung JA, Kim Y, Park K, Choi Y, Chae SW, Kim MG. Jin C, et al. Int J Clin Pharmacol Ther. 2014 Jan;52(1):64-72. doi: 10.5414/CP201991. Int J Clin Pharmacol Ther. 2014. PMID: 24290413 Clinical Trial.
Olmesartan medoxomil inhibits the vasoconstrictor effects of angiotensin II. ...OBJECTIVE: To assess bioequivalence between fixed-dose combination of olmesartan medoxomil and hydrochlorothiazide (HCTZ) in healthy Korean subjects. ...
Olmesartan medoxomil inhibits the vasoconstrictor effects of angiotensin II. ...OBJECTIVE: To assess bioequivalence between fixed-dos …
Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study.
Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, Guo W. Williams B, et al. Hypertension. 2017 Mar;69(3):411-420. doi: 10.1161/HYPERTENSIONAHA.116.08556. Epub 2017 Jan 16. Hypertension. 2017. PMID: 28093466 Clinical Trial.
The study extended double-blind treatment for 12 to 52 weeks, during which amlodipine (2.5-5 mg) and subsequently hydrochlorothiazide (6.25-25 mg) were added-on for patients not achieving blood pressure target (<140/90). ...After 52 weeks, blood pressure parameters were …
The study extended double-blind treatment for 12 to 52 weeks, during which amlodipine (2.5-5 mg) and subsequently hydrochlorothiazide …
Efficacy of Antihypertensive Drugs of Different Classes After Renal Denervation in Spontaneously Hypertensive Rats.
Hohl M, Lauder L, Sevimli Ö, Tokcan M, Wagmann L, Götzinger F, Schneider C, Hübner U, Lehnert U, Meyer MR, Böhm M, Mahfoud F. Hohl M, et al. Hypertension. 2023 Jun;80(6):e90-e100. doi: 10.1161/HYPERTENSIONAHA.122.20756. Epub 2023 Mar 31. Hypertension. 2023. PMID: 36999443
Ten days postsurgery, spontaneously hypertensive rats were randomized to receive no antihypertensive medication, amlodipine, olmesartan, hydrochlorothiazide, bisoprolol, doxazosin, or moxonidine for 28 days. ...At study end, mean arterial pressure was lower in RDN c …
Ten days postsurgery, spontaneously hypertensive rats were randomized to receive no antihypertensive medication, amlodipine, olmesartan …
Impact of Sex and Genetic Variation in Relevant Pharmacogenes on the Pharmacokinetics and Safety of Valsartan, Olmesartan and Hydrochlorothiazide.
Soria-Chacartegui P, Zubiaur P, Ochoa D, Navares-Gómez M, Abbes H, Villapalos-García G, de Miguel A, González-Iglesias E, Rodríguez-Lopez A, Mejía-Abril G, Martín-Vilchez S, Luquero-Bueno S, Román M, Abad-Santos F. Soria-Chacartegui P, et al. Int J Mol Sci. 2023 Oct 17;24(20):15265. doi: 10.3390/ijms242015265. Int J Mol Sci. 2023. PMID: 37894954 Free PMC article.
The study population were 64 volunteers from seven bioequivalence trials investigating formulations with valsartan, olmesartan and/or hydrochlorothiazide. Every volunteer was genotyped for 10 genetic variants in different transporters' genes. ...Sex impacted valsart …
The study population were 64 volunteers from seven bioequivalence trials investigating formulations with valsartan, olmesartan and/or …
266 results